Benlysta Market Growth Trajectory and Insights Through 2030
  Introduction to Benlysta (Belimumab)Benlysta (belimumab), developed by GlaxoSmithKline (GSK), is a monoclonal antibody designed to specifically target and inhibit B-lymphocyte stimulator (BLyS), a protein essential for B cell survival. Approved for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis, Benlysta has become a significant milestone in managing autoimmune...
0 Comentários 0 Compartilhamentos 88 Visualizações 0 Anterior